Antiplatelet therapy in neuroendovascular therapeutics

被引:39
作者
Fiorella, D
Thiabolt, L
Albuquerque, FC
Deshmukh, VR
McDougall, CG
Rasmussen, PA
机构
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Boston Sci Neurovasc, Fremont, CA 94538 USA
[3] Barrow Neurol Inst, Phoenix, AZ 85013 USA
关键词
D O I
10.1016/j.nec.2005.03.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Our understanding of the pharmacology of antiplatelet therapy continues to evolve rapidly. Although the existing data are primarily generated in the setting of interventional and preventative cardiology studies, these data may be extrapolated to guide the rational application of these agents in neuroendovascular procedures. Platelet function testing represents an increasingly available and practical method by which to verify the adequacy of therapy and guide clinical decision making. The optimal application of these agents will undoubtedly improve the risk profile of neuroendovascular procedures, increase the success rate of acute stroke intervention, and facilitate more effective secondary stroke prevention.
引用
收藏
页码:517 / +
页数:25
相关论文
共 102 条
[31]   MARKED PLATELET ACTIVATION INVIVO AFTER INTRAVENOUS STREPTOKINASE IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION [J].
FITZGERALD, DJ ;
CATELLA, F ;
ROY, L ;
FITZGERALD, GA .
CIRCULATION, 1988, 77 (01) :142-150
[32]  
FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247
[33]   RANDOMIZED PROSPECTIVE EVALUATION OF PROLONGED VERSUS ABBREVIATED INTRAVENOUS HEPARIN-THERAPY AFTER CORONARY ANGIOPLASTY [J].
FRIEDMAN, HZ ;
CRAGG, DR ;
GLAZIER, SM ;
GANGADHARAN, V ;
MARSALESE, DL ;
SCHREIBER, TL ;
ONEILL, WW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (05) :1214-1219
[34]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[35]  
Gawaz M, 1999, CIRCULATION, V99, P2
[36]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339
[37]   2-YEAR FOLLOW-UP OF ASPIRIN RESPONDER AND ASPIRIN NONRESPONDER - A PILOT-STUDY INCLUDING 180 POSTSTROKE PATIENTS [J].
GROTEMEYER, KH ;
SCHARAFINSKI, HW ;
HUSSTEDT, IW .
THROMBOSIS RESEARCH, 1993, 71 (05) :397-403
[38]   A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease [J].
Gum, PA ;
Kottke-Marchant, K ;
Welsh, PA ;
White, J ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) :961-965
[39]   Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial [J].
Gurbel, PA ;
Cummings, CC ;
Bell, CR ;
Alford, AB ;
Meister, AF ;
Serebruany, VL .
AMERICAN HEART JOURNAL, 2003, 145 (02) :239-247
[40]   Durability of platelet inhibition by Clopidogrel [J].
Gurbel, PA ;
Bliden, KP .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (09) :1123-1125